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Increase in Plasma Matrix Metalloproteinase-9 in Acute
Stroke Patients With Thrombolysis Failure
Ji Hoe Heo, MD, PhD; Seo Hyun Kim, MD; Kyung Yul Lee, MD; Eun Hee Kim, BS;
Chong Kyu Chu, MD; Jeong Mo Nam, PhD
Background and Purpose—Platelet-rich thrombi are resistant to thrombolytics. Matrix metalloproteinases (MMPs) may
be involved in platelet aggregation and contribute to thrombolysis failure in stroke patients.
Methods—Plasma samples from 23 stroke patients who had received thrombolytics and from 47 healthy volunteers were
examined for MMP-2 and MMP-9 by both enzyme-linked immunosorbent assays and zymography.
Results—The arteries were recanalized in 15 patients but not in the other 8. The MMP-9 plasma level was significantly
higher in patients whose arteries were not recanalized.
Conclusions—MMP-9 may be associated with the formation of a thrombolytics-resistant thrombus. (Stroke. 2003;34:e48-
e50.)
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The failure of thrombolytic-induced recanalization instroke patients is due partly to the resistance of thrombi
to lysis by the thrombolytic agents. Although few reports
have identified the factors associated with thrombolysis
failure, there is evidence suggesting that platelets play a role
in thrombolytic resistance.1
Matrix metalloproteinase (MMP) plays a key role in
remodeling the extracellular matrix. In addition, some evi-
dence suggests that MMPs are involved in platelet aggrega-
tion2,3 and atherosclerotic plaque rupture,4 which may lead to
the formation of platelet-rich thrombi.
Subjects and Methods
Among 57 stroke patients who had received thrombolytics during a
period of 2 years, 23 patients whose arterial recanalization could be
evaluated by angiography (21 by conventional angiography and 2 by
MR angiography) and whose blood could be obtained before
administration of the thrombolytics were prospectively enrolled in
this study. This included 7 patients with intravenous tissue-type
plasminogen activator (tPA), 5 with intra-arterial urokinase, and 11
with combined intravenous tPA and intra-arterial urokinase. The
institutional review board approved this study, and informed consent
was obtained. Arterial patency was assessed by the Thrombolysis in
Myocardial Infarction (TIMI) grading system, and patients were
grouped into nonrecanalization (TIMI 0 or 1) and recanalization
(TIMI 2 or 3).
The patients’ blood samples were obtained in a heparinized tube
when blood was drawn for the initial laboratory workup. Control
blood samples were obtained from volunteers 35 years of age at
their annual institutional health examinations. Blood samples were
examined for 47 volunteers, 23 men and 24 women, with a mean age
of 46 years after exclusion of those with a history of hypertension,
diabetes, stroke, coronary artery diseases, inflammatory diseases, or
malignancies and those with blood pressure 140/90 mm Hg,
fasting blood sugar 7.7 mmol/L (140 mg/dL), or total cholesterol
6.21 mmol/L (240 mg/dL). Blood samples were immediately
refrigerated and centrifuged at 3000 rpm for 15 minutes at 4°C, and
the plasma was stored at 80°C until analysis.
The MMP-2 and MMP-9 antigen levels were determined with a
commercially available enzyme-linked immunosorbent assay kit
(Biotrak, Amersham Biosciences) according to the manufacturer’s
protocol. Gelatin zymography was performed to confirm the enzyme
activities.5
The SAS system (version 8.2) was used for statistical analysis.
Significance was set at P0.05.
Results
The thrombolysis failed in 8 of the 23 patients. The demo-
graphic and clinical characteristics of the groups were similar
(the Table). The median delay from stroke onset to the time
when blood was taken was 106 minutes (range, 20 to 270
minutes).
The MMP-9 level was significantly different among the 3
groups. It was highest in the nonrecanalization group
(P0.0001 by the Kruskal-Wallis test) (Figure 1). The
median value was 311.6 ng/mL (interquartile range [IQR],
173.2 to 372.3) in the nonrecanalization group, 122.6 ng/mL
(IQR, 82.4 to 181.0) in the recanalization group, and 54.2
ng/mL (IQR, 28.2 to 98.0) in the control groups. In contrast,
the MMP-2 levels were similar among groups (P0.1741).
The most enzyme activities detected by zymography were
comparable to those of the latent MMP (Figure 2).
Hemorrhagic transformations occurred in 5 patients (2
symptomatic) who had higher plasma MMP-9 levels.
Received October 28, 2002; final revision received December 25, 2002; accepted January 20, 2003.
From the Departments of Neurology and Preventive Medicine (J.M.N.), Brain Korea 21 Project for Medical Science, Yonsei University College of
Medicine, Seoul, Korea.
Reprint requests to Ji Hoe Heo, MD, PhD, Department of Neurology, Yonsei University College of Medicine, Shinchon-dong 134, Seodaemoon-ku,
Seoul, 120-752, Korea. E-mail jhheo@yumc.yonsei.ac.kr
© 2003 American Heart Association, Inc.
Stroke is available at http://www.strokeaha.org DOI: 10.1161/01.STR.0000073788.81170.1C
1
 at CONS KESLI on July 22, 2014http://stroke.ahajournals.org/Downloaded from 
Discussion
This study demonstrated that the MMP-9 level was higher in
the plasma taken within the early hours after the stroke onset.
An increase in MMP-9 levels within 12 hours after onset has
been reported in cardioembolic stroke.6
High pretreatment plasma MMP-9 levels were associated
with thrombolytic resistance in this study. Platelet-rich
thrombi are resistant to thrombolytics.1 MMP is suggested to
be involved in platelet aggregation. MMP-1, MMP-2,
MMP-3, and MMP-9 have all been identified in human
platelets.7 The release of MMP-2 mediates platelet aggrega-
tion.3 MMP-1 acts as a signaling molecule that regulates the
thrombotic events by activating the platelets.2 Thromboem-
bolic occlusion of the rat middle cerebral artery causes
intravascular platelet-leukocyte aggregation in the ischemic
area, which coincides with the increase in MMP-9 and might
contribute to the time-dependent resistance to fibrinolysis.8 In
addition to the direct contribution of MMPs in platelet
aggregation, they may mediate the process of platelet-rich
thrombus formation in atherosclerotic vessels. Disruption of
atherosclerotic plaque depends partially on the MMP-9 ac-
tivities and amounts.4 This indicates that the increases in
MMP-9 levels in patients with thrombolysis failure might
represent its role in platelet-mediated thrombus formation
before and/or after an arterial occlusion, which can result in
ineffective thrombolysis.
Hemorrhagic transformations developed more commonly
in patients without recanalization. Of note, patients with
hemorrhagic transformation had significantly higher baseline
plasma MMP-9 levels. The potential role of MMP-9 in
hemorrhagic transformation has been demonstrated.5 Al-
though MMP-9 might act as a common denominator in both
ineffective thrombolysis and hemorrhagic transformation
during thrombolytic therapy, the sample size was too small to
draw proper conclusions.
This study has several limitations. There were a limited
number of patients with different thrombolytic treatment
regimens and routes. In addition, the sizes of the occluded
arteries were dissimilar. These might account for the lack of
statistical significance in certain variables such as the in-
volved arteries and the National Institutes of Health Stroke
Scale. Although this study showed for the first time that
increased MMP-9 levels are a potential plasma biomarker of
thrombolysis failure in strokes, it is unclear whether the
increased MMP-9 level contributed to the formation of
thrombolytics-resistant thrombi directly or was an epiphe-
nomenon of other factors. Therefore, further studies are
necessary to confirm this hypothesis.
Demographic Characteristics of the Patient Groups
Nonrecanalization
(n8)
Recanalization
(n15) P
Median age (range), y 71 (58–76) 61 (25–81) 0.16
Sex (men:women) 4:4 8:7 1.0
Risk factors, n
Hypertension 7 8 0.18
Diabetes mellitus 4 4 0.37
Smoking 1 6 0.35
Previous stroke 5 8 1.0
Cardiac embolic sources 6 7 0.38
Atrial fibrillation 5 5 0.22
LA swirling 1 4 0.62
Aorta plaques 0 4 0.26
Involved arteries, n 0.24
Middle cerebral artery 3 11
Internal carotid artery 3 2
Basilar artery 1 2
Posterior cerebral artery 1 0
Median time to (range), min
Blood sampling 113 (20–195) 90 (50–270) 0.93
Angiography 255 (205–300) 260 (80–405) 0.88
Treatment 170 (105–310) 145 (85–405) 0.35
Routes of thrombolysis, n 0.39
IV tPA 4 3
IA urokinase 1 4
IV tPA and IA urokinase 3 8
Median NIHSS (range) 21 (13–33) 17 (8–30) 0.54
HT, n 4 1 0.03
LA indicates left atrial; IV, intravenous; IA, intra-arterial; and NIHSS, National
Institutes of Health Stroke Scale. For comparison between groups, the Wilcoxon
2-sample test was used for age, time, and NIHSS; and Fisher’s exact test was
used for the others.
Figure 1. Plasma MMP-2 and MMP-9 levels in each group mea-
sured by an enzyme-linked immunosorbent assay.
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Figure 2. Representative zymogram
showing the MMP-2 and MMP-9 bands.
Std indicates recombinant MMP
standards.
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